Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats

Hideto To, Shigehiro Ohdo, Mikiko Shin, Hiroki Uchimaru, Eiji Yukawa, Shun Higuchi, Akio Fujimura, Eiji Kobayashi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Cardiac toxicity caused by doxorubicin (adriamycin) is a serious dose-limiting factor in the clinical situation. However, the influence of doxorubicin dosing time has not been clarified from the viewpoints of cardiotoxic development and its mechanism. In this study, we have investigated the dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity after repeated administration of doxorubicin in rats. When doxorubicin (5mgkg-1, i.p.) was administered every seven days (total of 30 mgkg-1) at 3, 9, 15 or 21 h after the light was turned on (HALO), toxic death was significantly higher in the 9 HALO treated group than the other groups. When doxorubicin was injected every seven days for 28 days at 9 or 21 HALO, we measured the levels of creatine kinase, malondialdehyde (MDA; an index of lipid peroxide), and glutathione peroxidase (GPx) as markers of cardiotoxicity. On days 14 and 28, creatine kinase levels were significantly higher in the 9-HALO group compared with the 21-HALO group (P<0.01, respectively). On day 14, MDA levels increased significantly in the 9 HALO group compared with the 21 HALO group (P<0.01). A single dose of doxorubicin was administered at 9-h or 21-h after the light was turned on to investigate the dosing-time-dependent difference of the pharmacokinetics. The area under the plasma time-concentration curve showed a significant increase at 9 HALO compared with 21 HALO (P<0.05). These results suggested that the dosing-time-dependent difference of cardiotoxicity induced by doxorubicin was closely related to the daily variation of doxorubicin pharmacokinetics. In conclusion, the choice of optimal dosing time based on the chronopharmacokinetics of doxorubicin may decrease the cardiotoxicity and enable the practice of effective and safe chemotherapy of doxorubicin.

Original languageEnglish
Pages (from-to)803-810
Number of pages8
JournalJournal of Pharmacy and Pharmacology
Volume55
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Doxorubicin
Bone Marrow
Light
Creatine Kinase
Cardiotoxicity
Pharmacokinetics
Lipid Peroxides
Poisons
Glutathione Peroxidase
Malondialdehyde
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats. / To, Hideto; Ohdo, Shigehiro; Shin, Mikiko; Uchimaru, Hiroki; Yukawa, Eiji; Higuchi, Shun; Fujimura, Akio; Kobayashi, Eiji.

In: Journal of Pharmacy and Pharmacology, Vol. 55, No. 6, 01.06.2003, p. 803-810.

Research output: Contribution to journalArticle

To, H, Ohdo, S, Shin, M, Uchimaru, H, Yukawa, E, Higuchi, S, Fujimura, A & Kobayashi, E 2003, 'Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats', Journal of Pharmacy and Pharmacology, vol. 55, no. 6, pp. 803-810. https://doi.org/10.1211/002235703765951410
To, Hideto ; Ohdo, Shigehiro ; Shin, Mikiko ; Uchimaru, Hiroki ; Yukawa, Eiji ; Higuchi, Shun ; Fujimura, Akio ; Kobayashi, Eiji. / Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats. In: Journal of Pharmacy and Pharmacology. 2003 ; Vol. 55, No. 6. pp. 803-810.
@article{5fc776ccfe504e1e852d1ac6f3febec3,
title = "Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats",
abstract = "Cardiac toxicity caused by doxorubicin (adriamycin) is a serious dose-limiting factor in the clinical situation. However, the influence of doxorubicin dosing time has not been clarified from the viewpoints of cardiotoxic development and its mechanism. In this study, we have investigated the dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity after repeated administration of doxorubicin in rats. When doxorubicin (5mgkg-1, i.p.) was administered every seven days (total of 30 mgkg-1) at 3, 9, 15 or 21 h after the light was turned on (HALO), toxic death was significantly higher in the 9 HALO treated group than the other groups. When doxorubicin was injected every seven days for 28 days at 9 or 21 HALO, we measured the levels of creatine kinase, malondialdehyde (MDA; an index of lipid peroxide), and glutathione peroxidase (GPx) as markers of cardiotoxicity. On days 14 and 28, creatine kinase levels were significantly higher in the 9-HALO group compared with the 21-HALO group (P<0.01, respectively). On day 14, MDA levels increased significantly in the 9 HALO group compared with the 21 HALO group (P<0.01). A single dose of doxorubicin was administered at 9-h or 21-h after the light was turned on to investigate the dosing-time-dependent difference of the pharmacokinetics. The area under the plasma time-concentration curve showed a significant increase at 9 HALO compared with 21 HALO (P<0.05). These results suggested that the dosing-time-dependent difference of cardiotoxicity induced by doxorubicin was closely related to the daily variation of doxorubicin pharmacokinetics. In conclusion, the choice of optimal dosing time based on the chronopharmacokinetics of doxorubicin may decrease the cardiotoxicity and enable the practice of effective and safe chemotherapy of doxorubicin.",
author = "Hideto To and Shigehiro Ohdo and Mikiko Shin and Hiroki Uchimaru and Eiji Yukawa and Shun Higuchi and Akio Fujimura and Eiji Kobayashi",
year = "2003",
month = "6",
day = "1",
doi = "10.1211/002235703765951410",
language = "English",
volume = "55",
pages = "803--810",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "6",

}

TY - JOUR

T1 - Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats

AU - To, Hideto

AU - Ohdo, Shigehiro

AU - Shin, Mikiko

AU - Uchimaru, Hiroki

AU - Yukawa, Eiji

AU - Higuchi, Shun

AU - Fujimura, Akio

AU - Kobayashi, Eiji

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Cardiac toxicity caused by doxorubicin (adriamycin) is a serious dose-limiting factor in the clinical situation. However, the influence of doxorubicin dosing time has not been clarified from the viewpoints of cardiotoxic development and its mechanism. In this study, we have investigated the dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity after repeated administration of doxorubicin in rats. When doxorubicin (5mgkg-1, i.p.) was administered every seven days (total of 30 mgkg-1) at 3, 9, 15 or 21 h after the light was turned on (HALO), toxic death was significantly higher in the 9 HALO treated group than the other groups. When doxorubicin was injected every seven days for 28 days at 9 or 21 HALO, we measured the levels of creatine kinase, malondialdehyde (MDA; an index of lipid peroxide), and glutathione peroxidase (GPx) as markers of cardiotoxicity. On days 14 and 28, creatine kinase levels were significantly higher in the 9-HALO group compared with the 21-HALO group (P<0.01, respectively). On day 14, MDA levels increased significantly in the 9 HALO group compared with the 21 HALO group (P<0.01). A single dose of doxorubicin was administered at 9-h or 21-h after the light was turned on to investigate the dosing-time-dependent difference of the pharmacokinetics. The area under the plasma time-concentration curve showed a significant increase at 9 HALO compared with 21 HALO (P<0.05). These results suggested that the dosing-time-dependent difference of cardiotoxicity induced by doxorubicin was closely related to the daily variation of doxorubicin pharmacokinetics. In conclusion, the choice of optimal dosing time based on the chronopharmacokinetics of doxorubicin may decrease the cardiotoxicity and enable the practice of effective and safe chemotherapy of doxorubicin.

AB - Cardiac toxicity caused by doxorubicin (adriamycin) is a serious dose-limiting factor in the clinical situation. However, the influence of doxorubicin dosing time has not been clarified from the viewpoints of cardiotoxic development and its mechanism. In this study, we have investigated the dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity after repeated administration of doxorubicin in rats. When doxorubicin (5mgkg-1, i.p.) was administered every seven days (total of 30 mgkg-1) at 3, 9, 15 or 21 h after the light was turned on (HALO), toxic death was significantly higher in the 9 HALO treated group than the other groups. When doxorubicin was injected every seven days for 28 days at 9 or 21 HALO, we measured the levels of creatine kinase, malondialdehyde (MDA; an index of lipid peroxide), and glutathione peroxidase (GPx) as markers of cardiotoxicity. On days 14 and 28, creatine kinase levels were significantly higher in the 9-HALO group compared with the 21-HALO group (P<0.01, respectively). On day 14, MDA levels increased significantly in the 9 HALO group compared with the 21 HALO group (P<0.01). A single dose of doxorubicin was administered at 9-h or 21-h after the light was turned on to investigate the dosing-time-dependent difference of the pharmacokinetics. The area under the plasma time-concentration curve showed a significant increase at 9 HALO compared with 21 HALO (P<0.05). These results suggested that the dosing-time-dependent difference of cardiotoxicity induced by doxorubicin was closely related to the daily variation of doxorubicin pharmacokinetics. In conclusion, the choice of optimal dosing time based on the chronopharmacokinetics of doxorubicin may decrease the cardiotoxicity and enable the practice of effective and safe chemotherapy of doxorubicin.

UR - http://www.scopus.com/inward/record.url?scp=0037530384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037530384&partnerID=8YFLogxK

U2 - 10.1211/002235703765951410

DO - 10.1211/002235703765951410

M3 - Article

C2 - 12841941

AN - SCOPUS:0037530384

VL - 55

SP - 803

EP - 810

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 6

ER -